News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
Lynx1 Capital Management LP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 06/02/2023 |
4
| Lynx1 Capital Management LP (10% Owner) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Sold 10,000 shares
@ $2.5148, valued at
$25.1k
Sold 15,000 shares
@ $2.5201, valued at
$37.8k
Sold 400 shares
@ $2.5075, valued at
$1k
|
|
| 06/02/2023 |
3
| Lynx1 Capital Management LP (10% Owner) has filed a Form 3 on TScan Therapeutics, Inc. |
| 06/02/2023 |
SC 13G
| Lynx1 Capital Management LP reports a 12.2% stake in TScan Therapeutics, Inc. |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 9.7% stake in Cabaletta Bio, Inc. |
| 02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 6.2% stake in Passage BIO, Inc. |
| 02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 7.6% stake in Pieris Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Lynx1 Capital Management LP reports a 6.8% stake in Alpine Immune Sciences, Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/23/2023 |
SC 13G
| Lynx1 Capital Management LP reports a 5% stake in Kinnate Biopharma Inc. |
| 01/23/2023 |
SC 13G
| Lynx1 Capital Management LP reports a 5% stake in Neoleukin Therapeutics, Inc. |
| 12/30/2022 |
SC 13G
| Lynx1 Capital Management LP reports a 5.4% stake in Neoleukin Therapeutics, Inc. |
| 11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 10/24/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/29/2022 |
SC 13G
| Lynx1 Capital Management LP reports a 5.1% stake in Passage BIO, Inc. |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/22/2022 |
SC 13G
| Lynx1 Capital Management LP reports a 5.1% stake in Alpine Immune Sciences, Inc. |
|
|